Drugs / Remlarsen
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02603224 | Nov 2015 → Apr 2017 | — | miRagen Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03601052 | Jun 2018 → Jun 2020 | keloid | miRagen Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Remlarsen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03601052 ↗ |
| Known as | MRG-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02603224 ↗ |
| Action | Inhibit | “decreases the expression of collagen and other proteins” NCT03601052 ↗ |